Technical Analysis for KURA - Kura Oncology, Inc.

Grade Last Price % Change Price Change
grade F 16.37 -0.43% -0.07
KURA closed down 0.43 percent on Friday, September 20, 2019, on 4.88 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Down Up
See historical KURA trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Volume Surge Other 0.00%
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
Bearish Engulfing Bearish -0.43%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.43%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.44%
200 DMA Support Bullish -1.44%
Overbought Stochastic Strength -1.44%

Older signals for KURA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.
Medicine Cancer Oncology Solid Tumors Cancers Cell Signaling Signal Transduction Oncogenes Benzamides Ras Subfamily Blood Cancers Braf Kras
Is KURA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 21.42
52 Week Low 10.2
Average Volume 280,458
200-Day Moving Average 16.3763
50-Day Moving Average 17.6742
20-Day Moving Average 15.8635
10-Day Moving Average 16.265
Average True Range 0.6531
ADX 16.87
+DI 18.7383
-DI 18.886
Chandelier Exit (Long, 3 ATRs ) 15.9107
Chandelier Exit (Short, 3 ATRs ) 16.8893
Upper Bollinger Band 16.8789
Lower Bollinger Band 14.8481
Percent B (%b) 0.75
BandWidth 12.801715
MACD Line -0.2786
MACD Signal Line -0.4775
MACD Histogram 0.1989
Fundamentals Value
Market Cap 327.2 Million
Num Shares 20 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -10.70
Price-to-Sales 0.00
Price-to-Book 6.41
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.45
Resistance 3 (R3) 17.44 17.08 17.27
Resistance 2 (R2) 17.08 16.80 17.08 17.21
Resistance 1 (R1) 16.72 16.63 16.54 16.73 17.15
Pivot Point 16.36 16.36 16.27 16.36 16.36
Support 1 (S1) 16.00 16.08 15.82 16.01 15.59
Support 2 (S2) 15.64 15.91 15.64 15.53
Support 3 (S3) 15.28 15.64 15.47
Support 4 (S4) 15.29